|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6C
|
|
pubmed:dateCreated |
2008-1-24
|
|
pubmed:abstractText |
Mutations in the BRCA1/2 genes confer a high risk for breast and ovarian cancer, with usually adverse clinical characteristics. The clinical course and response to treatment in mutation carriers have been reported infrequently and are assumed to be worse than in sporadic breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4295-300
|
|
pubmed:meshHeading |
pubmed-meshheading:18214034-Base Sequence,
pubmed-meshheading:18214034-Breast Neoplasms,
pubmed-meshheading:18214034-DNA Mutational Analysis,
pubmed-meshheading:18214034-Female,
pubmed-meshheading:18214034-Finland,
pubmed-meshheading:18214034-Genes, BRCA2,
pubmed-meshheading:18214034-Genetic Predisposition to Disease,
pubmed-meshheading:18214034-Haplotypes,
pubmed-meshheading:18214034-Heterozygote,
pubmed-meshheading:18214034-Humans,
pubmed-meshheading:18214034-Mutation,
pubmed-meshheading:18214034-Ovarian Neoplasms,
pubmed-meshheading:18214034-Pedigree,
pubmed-meshheading:18214034-Prognosis,
pubmed-meshheading:18214034-Treatment Outcome
|
|
pubmed:articleTitle |
A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.
|
|
pubmed:affiliation |
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Finland. jaana.hartikainen@uku.fi
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
